FDMT: 2-Yr Follow-Up from Phase I/II Shows Continued Durability and Supports Our Conviction 4D-150 Is a Best-in-Class Drug

Research evidence excerpt

FDMT: 2-Yr Follow-Up from Phase I/II Shows Continued Durability and Supports Our Conviction 4D-150 Is a Best-in-Class Drug

is not for general

distribution in the United Kingdom to retail clients, as defined under the rules of the FCA. RBCEL accepts responsibility for this report and its dissemination in

the United Kingdom.

To EEA Residents:

This material is distributed in the EU by either RBCEL on an authorised cross-border basis, or by RBC Capital Markets (Europe) GmbH (RBC EG) which is authorised

and regulated in Germany by the Bundesanstalt für Finanzdienstleistungsaufsicht (German Federal Financial Supervisory Authority) (BaFin).

To Persons Receiving This Advice in Australia:

This material has been distributed in Australia by Royal Bank of Canada, Sydney Branch (ABN 86 076 940 880, AFSL No. 246521). This material has been prepared for

general circulation and does not take into account the objectives, financial situation or needs of any recipient. Accordingly, any recipient should, before acting on

this material, consider the appropriateness of this material having regard to their objectives, financial situation and needs. If this material relates to the acquisition

or possible acquisition of a particular financial product, a recipient in Australia should obtain any relevant disclosure document prepared in respect of that product

and consider that document before making any decision about whether to acquire the product. This research report is not for retail investors as defined in section

761G of the Corporations Act.

To persons receiving this from Royal Bank of Canada, Hong Kong Branch:

This document is distributed in Hong Kong by Royal Bank of Canada, Hong Kong Branch which is regulated by the Hong Kong Monetary Authority and the Securities